This article is a correction to:
Applying new approach methodologies to assess next-generation tobacco and nicotine products
David Thorne
Damian McHugh2
Hitoshi Fujimoto
Sara Moses
Marianna Gaca- 1BAT (Investments) Ltd., Southampton, Hampshire, United Kingdom
- 2PMI R&D Philip Morris Products S. A., Neuchâtel, Switzerland
- 3Imperial Brands, Bristol, United Kingdom
- 4Altria Client Services LLC, Richmond, VA, United States
- 5Japan Tobacco Inc., R&D Group, Yokohama, Kanagawa, Japan
- 6Swedish Match, Stockholm, Sweden
A Corrigendum on
Applying new approach methodologies to assess next-generation tobacco and nicotine products
by Thorne D, McHugh D, Simms L, Lee KM, Fujimoto H, Moses S and Gaca M (2024). Front. Toxicol. 6:1376118. doi: 10.3389/ftox.2024.1376118
In the published article, there was an error in the Conflict of interest statement. The Conflict of interest statement was displayed as “Authors DT and MG were employed by BAT (Investments) Ltd. Author LS was employed by Imperial Brands. Author KML was employed by Altria Client Services LLC. Author HF was employed by Japan Tobacco Inc., R&D Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The correct Conflict of interest statement appears below.
Conflict of interest
Authors DT and MG were employed by BAT (Investments) Ltd. Author LS was employed by Imperial Brands. Author KL was employed by Altria Client Services LLC. Author HF was employed by Japan Tobacco Inc., R&D Group. Author DM was employed by Philip Morris International. Author SM was employed by Swedish Match.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: new approach methodologies (NAM), organs on a chip (OoC), human 3D tissues, next-generation products (NGP), airway models, high-content analysis, adverse outcome pathway (AOP), dosimetry
Citation: Thorne D, McHugh D, Simms L, Lee KM, Fujimoto H, Moses S and Gaca M (2024) Corrigendum: Applying new approach methodologies to assess next-generation tobacco and nicotine products. Front. Toxicol. 6:1460271. doi: 10.3389/ftox.2024.1460271
Received: 05 July 2024; Accepted: 09 July 2024;
Published: 19 July 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Thorne, McHugh, Simms, Lee, Fujimoto, Moses and Gaca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marianna Gaca, marianna_gaca@bat.com